Thrombocytopenia Associated With Teicoplanin Use: A Retrospective Observational Study.

Area of Science:

• Pharmacology
• Clinical Pharmacy
• Infectious Diseases

Background:

• Contradictory studies report varied incidence rates of teicoplanin-induced thrombocytopenia (TIT).
• Understanding the true incidence and risk factors for TIT is crucial for patient safety.

Purpose of the Study:

• To determine the incidence of teicoplanin-induced thrombocytopenia (TIT) within a specific dosing range (6-12 mg/kg/dose).
• To identify potential risk factors associated with the development of TIT.

Main Methods:

• Retrospective observational study of 482 adult patients receiving teicoplanin for ≥3 consecutive days.
• Thrombocytopenia defined as platelet count <100 × 10³/µL with ≥25% drop from baseline.
• Incidence assessed using the Naranjo scale for adverse drug reaction probability.

Main Results:

• The overall incidence of TIT was 4.6% (possible and probable categories).
• Median time to platelet drop was 5 days, with maximum drop at 8 days.
• No patient variables were independently associated with increased TIT risk.

Conclusions:

• Teicoplanin-induced thrombocytopenia (TIT) occurs at a low incidence, even in critically ill patients.
• These findings support optimal monitoring strategies for teicoplanin therapy to detect serious adverse effects.